Caliber Imaging & Diagnostics Inc · OTC:LCDX

Caliber Imaging & Diagnostics — Investor Presentation (April 2014)

17 slides from Caliber Imaging & Diagnostics's investor presentation, April 2014

  1. Slide 1: Corporate Overview

    Corporate Overview April 2014 OTCQB: LCDX

  2. Slide 2: Company Snapshot

    Company Snapshot  Provides non-invasive, point-of-care cellular imaging technologies biopsy  VivaScope® systems can improve patient outcomes while reducing costs to the healthcare system  VivaScope is a Standard of Care in Germany with the S1 guidelines  VivaScope® provides physicians with a pow

  3. Slide 3: Caliber I.D. Brand Promise

    Caliber I.D. Brand Promise  The VivaScope system provides accurate diagnostic information without the need for biopsies  Accurately lets physicians identify areas that need to be treated  Evaluate the wound healing process and monitors therapeutic outcomes  Unlike biopsies, permits unlimited rep

  4. Slide 4: Investment Thesis

    Investment Thesis  VivaScope is a proprietary platform directed to multiple large markets  Academic, Medical and Therapeutic Research  Caliber I.D. estimates the immediate market opportunity to be $300 million  Sales to drug and cosmetic industry  VivaScope competitively priced against conventi

  5. Slide 5: Technology: VivaScope Cellular Imaging

    Technology VivaScope® Cellular Imaging Pinhole and Detector  Confocal Cellular Imaging  Creates layer-by-layer scans of living tissue, with a >0.2mm imaging depth  Provides a microscopic view of living cells in the skin, with a 3-5 micron cellular resolution, comparable to Laser histology Scannin

  6. Slide 6: Technology: VivaScope Product Platform

    Technology VivaScope® Product Platform In Vivo Cellular Video In Vivo Cellular Ex Vivo Cellular Telepathology Imager Dermoscopy Imager Imager VivaScope® 1500 VivaNet® / and VivaScope® VivaCam® VivaScope® 3000 VivaScope® 2500 VivaLAN 1500 Multi Laser FDA 510(k) cleared FDA 510(k) cleared FDA 510(k) e

  7. Slide 7: Immediate Commercialization Strategy

    Immediate Commercialization Strategy Academic, Medical and Therapeutic Research  Opportunity to capture research sales currently going to major microscopy manufacturers  Caliber I.D.’s confocal imaging provides a cost-effective solution to pre-clinical research, whereby researchers may view tissue

  8. Slide 8: Immediate Commercialization Strategy

    Immediate Commercialization Strategy Academic, Medical and Therapeutic Research Current customers include some of the most highly regarded Fortune 500 companies, and academic institutions Over 300 units shipped into commercial research and academic markets Cosmetic Academia – Proctor & Gamble – Ri

  9. Slide 9: Near-Term Commercialization Strategy

    Near-Term Commercialization Strategy Skin Cancer Screening and Diagnosis  Skin cancer is the most prevalent cancer in the United States  3.5 million new cases annually and a lifetime incidence rate of 20%  Exceeds the combined incidence of breast, prostate, lung and colon cancers  Conventionally

  10. Slide 10: Near-Term Commercialization Strategy

    Near-Term Commercialization Strategy Skin Cancer Screening and Diagnosis  Independent skin cancer screening clinics  Developing market across healthcare continuum  For the first time patients will have an option and preference for an alternative to biopsy!  Potential source of high margin, recur

  11. Slide 11: Near-Term Commercialization Strategy

    Near-Term Commercialization Strategy Skin Cancer Screening and Diagnosis Benign Mole Basal Cell Carcinoma  Images can be interpreted by the physician at the point of patient care, and/or  Images can be securely transferred to a private-network pathologist for remote diagnosis Melanoma Squamous Cel

  12. Slide 12: Longer-Term Commercialization Strategy

    Longer-Term Commercialization Strategy Surgical and Therapeutic Management  In therapeutic monitoring, VivaScope allows physicians to repeatedly and nondestructively examine tissue to determine the effectiveness of therapy in real time  In surgery, the technology can enable surgeons to identify, d

  13. Slide 13: Growth Strategy

    Growth Strategy • Caliber I.D. is a unique platform-technology company that has the ability to address multiple high growth markets in drug research and in the cancer diagnosis/treatment markets and in clinical medicine • Initially Caliber I.D. is focused on the research market, followed by the clin

  14. Slide 14: Approaching Milestones

    Approaching Milestones  Continue execution/rollout of Research Sales team - 2014  Opening first independent Imaging Center in May 2014  Develop and support the launch of Independent Imaging Centers across the U.S. – Q2 ‘14  Complete NCI - sponsored Melanoma study – H2 ‘14  Seek partnership with

  15. Slide 15: Key Financial Data

    Key Financial Data Equity Metrics (April 2014) Balance Sheet (12/31/13)  Market cap: $5.45 million  Current assets: $2.3 million  Shares outstanding: 8.5 million  Debt: $11.8 million (1) Revenue  12 mos. ended 12/31/13: $3.3 million  12 mos. ended 12/31/12: $2.4 million 1 Principal of $5M plus

  16. Slide 16: Investment Thesis - Recap

    Investment Thesis - Recap  VivaScope is a proprietary platform directed to multiple large markets  Academic, Medical and Therapeutic Research  Immediate market opportunity of $300 million  Sales to drug and cosmetic industry  VivaScope competitively priced against conventional technology provid

  17. Slide 17: Forward-Looking Statements

    Forward-Looking Statements This corporate overview contains statements about Caliber Imaging & Diagnostics’ or Caliber I.D.’s future expectations, plans and prospects that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 2

Caliber Imaging & Diagnostics — Investor Presentation (April 2014) on 6ix